

AUSTRALIA
Patents Act 1990

NOTICE OF ENTITLEMENT

We PHARMACIA & UPJOHN S.p.A. (005 501 155)

of Via Robert Koch 1.2., 20152 MILAN, ITALY

being the Applicant and Nominated Person, in respect of Application No. 72290/94, entitled PROCESS FOR THE PREPARATION OF 9-AMINO CAMPTOTHECIN state the following:

Angelo Bedeschi; Walter Cabri; Ilaria Candiani and Franco Zarini are the actual inventors of the invention the subject of the Application.

The inventors made the invention for and on behalf of Farmitalia Carlo Erba S.r.l. in the course of their duties as employees of Farmitalia Carlo Erba S.r.l. Farmitalia Carlo Erba S.r.l. subsequently merged into Pharmacia S.p.A. Pharmacia S.p.A. subsequently changed its name to Pharmacia & Upjohn S.p.A.

Farmitalia Carlo Erba S.r.l. is the applicant of the application listed in the declaration under Article 8 of the PCT.


Convention priority is claimed from the following basic application(s) referred to in the declaration under Article 8 of the PCT:

Basic Applicant	Application Number	Application Date	Country	Country Code
Farmitalia Carlo Erba S.r.l.	9316352	6 August 1993	United Kingdom	GB

The basic application referred to in the declaration under Article 8 of the PCT was the first application made in a Convention country in respect of the invention the subject of the Application.

DATED this 19th day of February 1997

PHARMACIA & UPJOHN S.p.A.
By their Patent Attorney


GRIFFITH HACK

OUR REF: P04261-NV



AU9472290


(12) PATENT ABRIDGMENT (11) Document No. AU-B-72290/94
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 678587

- (54) Title
PROCESS FOR THE PREPARATION OF 9-AMINO CAMPTOTHECIN
- International Patent Classification(s)
(51)⁶ C07D 491/22
- (21) Application No. : 72290/94 (22) Application Date : 18.07.94
- (87) PCT Publication Number : WO95/04736
- (30) Priority Data
- | | | |
|-------------|-----------|-------------------|
| (31) Number | (32) Date | (33) Country |
| 9316352 | 06.08.93 | GB UNITED KINGDOM |
- (43) Publication Date : 28.02.95
- (44) Publication Date of Accepted Application : 05.06.97
- (71) Applicant(s)
PHARMACIA & UPJOHN S.P.A.
- (72) Inventor(s)
ANGELO BEDESCHI; WALTER CABRI; ILARIA CANDIANI; FRANCO ZARINI
- (74) Attorney or Agent
GRIFFITH HACK, GPO Box 4164, SYDNEY NSW 2001
- (57)

9 amino-20 (s) -camptothecin is an antitumour agent

CLAIM


1. A process for preparing the 9-amino camptothecin of formula (I)



(I)


said process comprising:

- (1) reducing the compound of formula (II)




(II)

so obtaining the compound of formula (III)



(III)

- (2) converting the compound of formula (III) into a
compound of formula (IV)




(IV)

wherein

X is a group which can be reductively removed;

- (3) reacting a compound of formula (IV) with a
nitrating agent, so obtaining a compound of
formula (V)




(V)

wherein X is as defined above;

and

- (4) reducing in a single step a compound of formula (V), so obtaining the 9-amino camptothecin of formula (I) or, alternatively,
- (5) reducing a compound of formula (V), so obtaining a compound of formula (VI)



(VI)

wherein X is as defined above, and

- (6) reductively removing the X group from a compound of formula (VI), so obtaining the 9-amino camptothecin of formula (I).
8. A process for the preparation of the 9-amino camptothecin of formula (I) as defined in claim 1, which process comprises
- (i) reducing a compound of formula (V) as defined in claim 1 under such conditions that 9-amino camptothecin is formed in a single step; or
 - (ii) reductively removing the X group from a compound of formula (VI) as defined in claim 1.
13. A compound of formula (V) or (VI) as defined in claim 1.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, the 9-amino camptothecin of formula (I) as defined in claim

(11) AU-B-72290/94
(10) 678587

- 4 -

1 which has been prepared by a process as
claimed in any one of claims 1 to 12.

OPI DATE 28/02/95 APPLN. ID 72290/94
AOJP DATE 13/04/95 PCT NUMBER PCT/EP94/02370



AU9472290


Li

1)

(51) International Patent Classification ⁶ : C07D 491/22		A1	(11) International Publication Number: WO 95/04736
			(43) International Publication Date: 16 February 1995 (16.02.95)
(21) International Application Number: PCT/EP94/02370		(81) Designated States: AU, CA, CN, FI, HU, JP, KR, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 18 July 1994 (18.07.94)			
(30) Priority Data: 9316352.5 6 August 1993 (06.08.93) GB		Published With international search report.	
(71) Applicant: <i>Pharmacia - Upjohn S.p.A.</i> PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, no. 1.2., I-20152 Milano (IT).		 678587	
(72) Inventors: BEDESCHI, Angelo; Via Pietro Redaelli, 11, I-20146 Milano (IT). CABRI, Walter; Via Massimo D'Azeglio, 29, I-20089 Rozzano (IT). CANDIANI, Ilaria; Via Don D. Albertario, 5, I-21052 Busto Arsizio (IT). ZARINI, Franco; Via Giuseppe Di Vittorio, 41, I-20019 Settimo Milanese (IT).			
(54) Title: PROCESS FOR THE PREPARATION OF 9-AMINO CAMPTOTHECIN			
 (IV)			
(57) Abstract			
9-amino-20(S)-camptothecin (I) is prepared by reducing 12-nitro-20(S)-camptothecin (II); converting the resulting 12-amino-20(S)-camptothecin (III) into a compound of formula (IV) wherein X is a group which can be reductively removed; reacting the compound of formula (IV) with a nitrating agent, to obtain thereby the corresponding 9-nitro-20(S)-camptothecin compound of formula (V) substituted at the 12-position by the group X; reducing in a single step the compound of formula (V), so obtaining the 9-amino-20(S)-camptothecin of formula (I); or reducing the compound of formula (V), so obtaining the corresponding 9-amino-20(S)-camptothecin compound of formula (VI) substituted at the 12-position by the group X and reductively removing the X group from the compound of formula (VI), so obtaining 9-amino-20(S)-camptothecin.			

PROCESS FOR THE PREPARATION OF 9-AMINO CAMPTOTHECINField of the invention

The present invention relates to a new process for
5 the preparation of 9-amino-20 (S)-camptothecin of formula
(I)



(I)

10

which is a known antitumor agent: Wani et al., J. Med.
Chem. 1987, 30, 1774-1779; Hsiang et al., Cancer Res. 49,
4385-4389, August 15, 1989; Cancer Res. 49, 1465-1469,
15 March 15, 1989.

Background of the invention

Totally synthetic approaches to 9-amino camptothecin
have been widely described (US -A- 4,894,456 and US -A-
5,053,512). Total synthesis of the product, however, is
20 neither desirable nor suitable for large scale production
because it involves too many process steps that make the
synthesis too long and, especially, too expensive.

A semisynthetic approach to 9-amino camptothecin is
described, e.g., in JP -A- 59-51289, published in 1984,
25 starting from the known natural product camptothecin:
Cancer Chemotherapy Reports, part I, vol. 54, No. 6, Dec.
1970, 461-470; J. Med. Chem., 1980, 23, 554-560; Science,

vol. 246, Nov. 1989, 1046-1048. The said semisynthetic approach involves the nitration of the naturally occurring camptothecin, followed by reduction of the 9-nitro derivative. That nitration, however, initially
5 produces a 70/30 mixture of the undesired 12-nitro camptothecin derivative (70%) and of the desired 9-nitro camptothecin derivative (30%). The 9-nitro derivative is therefore formed only in a minor amount.

After the separation of the two nitration products,
10 the 12-nitro derivative, which is itself biologically inactive (see, for instance, Wani C., Nicholas A.W., Wall M.E., J. Med. Chem., 1986, 29, 2358), must then be discharged, giving rise to waste treatment problems. The considerable drawback concerning the removal of the
15 undesired 12-nitro derivative byproduct is particularly relevant for large scale production since large amounts of unuseful 12-nitro derivative are collected and need to be eliminated.


Moreover, following this semisynthetic approach,
20 large quantities of natural camptothecin, which is highly expensive, are needed to produce small quantities of the desired antitumor agent 9-amino camptothecin. The low overall productivity and yields of this approach make the production of substantial amounts of the desired compound
25 difficult. There is therefore a need for a process permitting increased productivity and yields compared to the above outlined semisynthetic approach to 9-amino

camptothecin.

We have developed a new process which fulfils this purpose and, at the same time, resolves the waste product problems deriving from the production of consistent amounts of the undesired 12-nitro derivative. According to the invention, this 12-nitro derivative is recycled into the process through conversion into 9-amino camptothecin by easy and mild reaction conditions ensuring high yields and clean reaction products.

Accordingly, the present invention provides a new process for preparing 9-amino camptothecin of formula (I) starting from 12-nitro camptothecin of formula (II), according to the steps illustrated in Scheme I below:

Scheme I



wherein X is a group which can be removed reductively.

The process includes the reductive transformation of the 12-nitro derivative of formula (II), into the 12-amino derivative of formula (III). This intermediate is in turn transformed into the corresponding diazo derivative, which is "in situ" transformed into a compound of formula (IV), wherein X is a group which can be reductively removed, e.g. a halogen.

Nitration of the 12-substituted derivative of formula (IV) affords with high selectivity and yields the corresponding 9-nitro-12-substituted derivative of formula (V). The subsequent reduction of the compound of formula (V) to give the 9-amino camptothecin compound of formula (I) may be performed either in a single step leading directly the compound of formula (I) or, alternatively, in two steps reducing first a compound of formula (V) to a compound of formula (VI) and, further, reducing a compound of formula (VI) to the compound of formula (I). The compound of formula (VI) may not be necessarily isolated.

In JP-A-59-51289 cited above and in published literature articles (see for instance Chem. Pharm. Bull. 1991, 39, 3183) much chemistry has been disclosed about the camptothecin molecule, including conversion of the 12-amino group into a corresponding 12-halo derivative, but it was used only for the purpose of synthesizing compounds for biological evaluation. The biological uselessness of the 12 substituted compounds (see, for

instance Crow, R.T.; Crothers, D.M. J. Med. Chem. 1992, 35, 4160), and the chemical difficulties have then prevented any effort toward possible further modifications of the 12-substituted camptothecin derivatives.

In particular, the introduction of a nitro group on a 12-substituted derivative of this molecule is not known and looks problematic as it could give rise to mixtures of derivatives: different positions of the ring system, in fact, could undergo to reaction.


Furthermore, with reference to the removal of the X group from the compound (V) or (VI) it must be emphasized that, while the reductive removal of halogen atoms from quinolines is well known (see for instance Jones, G. The Chemistry of heterocyclic compounds, 32, I. p. 604-611) where, generally, the presence of bases is regarded as beneficial in order to achieve mild reaction conditions, on the contrary, in spite of the several years effort on the chemistry of camptothecin, nothing is known about group removal (e.g. removal of halogen groups) from camptothecin derivatives, and, more, camptothecin derivatives are known to be extremely base sensitive so that the recourse to a base would appear problematic.

Surprisingly we have now found that it is possible to remove, e.g., a halogen atom from camptothecin in the presence of an organic or inorganic non-nucleophilic base. The present invention includes this aspect and is

also based on the observation of the very weak basic and nucleophilic nature of the 9-amino group in camptothecin molecule. Indeed, the reduction of the 9-nitro group in 9-nitro-12-substituted derivatives of formula (V) would afford the 9-amino functionality and the so formed 9-amino group could then act as an in situ generated weak non-nucleophilic base, and, in principle, promote the reductive removal of group X, without decomposition.

On the other hand, the presence of the two substituents in the p-position to each other in a compound of formula (V) could be expected to have an undesired influence, and impede or render very difficult the double reduction step; low yields or decomposition of the desired product could be expected. In any case, the overall synthetic scheme illustrated above combining such a sequence of reactions, has never been reported, nor has its potential utility been recognized or exploited before.

The present invention according to one aspect provides a process for preparing 9-amino camptothecin of formula (I)




(I)

said process comprising:

7


(1) reducing the compound of formula (II)



(II)

5


so obtaining the compound of formula (III);



(III)

10

(2) converting the compound of formula (III) into a compound of formula (IV)



(IV)


15

wherein

X is a group which can be reductively removed;

(3) reacting a compound of formula (IV) with a nitrating agent so obtaining a compound of formula (V)

20



(V)

25

wherein X is as defined above,


and

(4) reducing in a single step a compound of formula (V)

so obtaining the 9-amino camptothecin of formula (I)
or, alternatively,

- (5) reducing a compound of formula (V) so obtaining a
compound of formula (VI)

5



(VI)

10 wherein X is as defined above, and

- (6) reductively removing the X group from a compound of
formula (VI) so obtaining the 9-amino camptothecin of
formula (I).

Preferably the X group is a halogen, such as, e.g., Cl,
15 I, Br or F, more preferably Cl or Br.

The reduction of the compound of formula (II) into
the compound of formula (III) may be carried out, for
example, with suitable reducing agents, or by catalytic
reduction with suitable catalysts, in the presence of
20 suitable reducing agents. For example, it may be
performed as described in: J. March, Advanced Organic
Chemistry, Third Edition, 1103. For instance, the
reduction may be performed with reducing agents such as,
e.g., SnCl_2 , or other metals or metal salts, such as,
25 e.g., Zn or Fe and their salts, in a suitable solvent
such as, e.g., dilute or concentrate aqueous HCl, dilute
aqueous protic acids, water, ethanol, methanol, or

mixtures thereof, at a temperature of from about -20°C to about 60°C, for a period which may vary from a few minutes to several days such as from about 5 minutes to about 3 days, for example from 4 hours to 24 hours; or by
5 the use of catalytic amounts of metals which perform nitro group reduction, such as, e.g., palladium, platinum oxide, platinum, rhodium or ruthenium, in the presence of molecular hydrogen or hydrogen sources, such as, e.g., triethylammonium formate, formic acid, tributyltin
10 hydride, cyclohexadiene, etc., in a suitable solvent, such as, e.g., dimethylformamide (DMF), MeOH, acetic acid, CHCl₃, dioxane, or mixtures thereof, at a temperature of from about 0°C to about 100°C, for a time of from a few minutes, such as, e.g., 5 minutes, until H₂
15 consumption has ceased, e.g., about 3 days, and at a pressure of from about 1 atm to about 100 atm.

The conversion of the compound of formula (III) into a compound of formula (IV) may be carried out with a suitable reagent such as, for example, a copper(I)
20 halide, through the formation of a diazoderivative which does not need to be isolated from the reaction mixture. The diazotisation reaction may be performed by the use of suitable diazotising agents, such as, e.g., NaNO₂ or organic nitrites in aqueous dilute protic acids, such as,
25 e.g., HCl, HBr or H₂SO₄, or in organic solvents, at a temperature of from about -20°C to about 100°C, for a

period which may vary from a few minutes to several hours, such as from about 5 minutes to about 24 hours. The resulting solution may then be reacted with from a stoichiometric amount to a large excess, for example up to a 10-fold molar excess, of a copper(I) halide, such as, e.g., CuCl or CuBr, or with iodide ions, optionally in the presence of an aqueous solution of the corresponding hydrogen halide acid that can be used as solvent, at a temperature of from about 0°C to about 100°C, for a time which may vary from a few minutes to 1 day, such as from about 5 minutes to about 1 day.

The nitration of a compound of formula (IV) to obtain a compound of formula (V) may be performed with a nitrating agent, such as, e.g., nitric acid, mixtures of nitric and sulphuric acid, or other nitrating agents, such as, e.g., potassium nitrate or nitric acid and boron trifluoride, such as, boron trifluoride monohydrate (see for instance Olah, G.A., et al. Synthesis 1085, 1992), or nitric acid/trifluoromethanesulfonic anhydride (ibid., 1087, 1992), at a temperature of from about -20°C to about 100°C, for a time which may vary from a few minutes to several days, such as from about 5 minutes to about 3 days, for example from about 4 hours to about 24 hours.

The single step reduction of a compound of formula (V) into the compound of formula (I) may be performed with suitable reducing agents, such as, e.g., molecular hydrogen or triethylammonium formate, formic acid,

tributyltin hydride, cyclohexadiene, etc., in the presence of suitable catalysts either in homogeneous conditions, e.g., in the presence of palladium or platinum salts and of suitable phosphorus or nitrogen ligands, or heterogeneous conditions, e.g., in the presence of palladium, platinum oxide, platinum, rhodium or ruthenium as such, or supported on a suitable medium, such as, e.g., on carbon, on CaCO_3 , on BaSO_4 , on alumina, etc., in a suitable solvent such as, e.g., DMF, MeOH, acetic acid, CHCl_3 , dioxane, or mixtures thereof, at a temperature of from about 0°C to about 100°C , for a time which may vary from about 1 hour to about 3 days, and at a pressure of from about 1 atm to about 100 atm, optionally in the presence of an inorganic or organic base.

When alternatively the reduction of a compound of formula (V) into the compound of formula (I) is carried out in two separate steps, the first step may be performed with suitable reducing agents such as, e.g., those described above for the single step reduction of a compound of formula (V), for shorter times, e.g., for times of from a few minutes to several hours, such as from about 5 minutes to about 24 hours, if desired, isolating the intermediate derivative of formula (VI) and then performing the further reductive step of a compound of formula (VI) following the same reductive procedure

described above for the reduction of a compound of formula (V) in a single step; or by means of reagents which give radical removal of halogens, such as, e.g., $n\text{-Bu}_3\text{SnH}$ in the presence of a radical initiator, such as, e.g., 2,2'-azobisisobutyronitrile (AIBN), or tris(trimethyl)silane, etc., in suitable solvents such as, e.g., benzene, toluene, CHCl_3 , acetonitrile, DMF, or mixtures thereof, at a temperature which may vary from room temperature to solvent reflux temperature, for a time of a few minutes to several hours, such as, from about 5 minutes to about 24 hours.

Preferred reducing agents for the reduction from the compound of formula (II) to the compound of formula (III) are, e.g., SnCl_2 , in dilute or concentrated aqueous HCl , at a temperature of from about 0°C to about 60°C for a period of from about 1 hour to about 2 days; or, by means of catalytic reduction, 5 or 10% Pd/C and molecular hydrogen in DMF, or PtO_2 and molecular hydrogen, at a temperature of from room temperature to about 60°C for a time of from about 1 hour to about 24 hours, and with a hydrogen pressure of from about 1 atm to about 10 atm.

Preferred reagents for the conversion of the compound of formula (III) into a compound of formula (IV) are, e.g., NaNO_2 , amyl nitrite, tert-butyl nitrite, or organic nitrites, in aqueous or organic solvents such as, e.g., conc. HCl or HBr , dilute HCl or HBr , DMF, dioxane or

CH₂Cl₂, at a temperature of from about -20°C to about 60°C, for a time of from about 10 minutes to about 12 hours. The resulting solution may then be reacted with from a stoichiometric amount to 10 equiv. of copper(I) halide, such as, e.g., CuCl or CuBr, or with iodide ions, optionally in the presence of aqueous solutions of the corresponding hydrogen halide acids that can be used as solvents, at a temperature of from room temperature to about 80°C, for a time which may vary from a few minutes to a few hours, such as from about 5 minutes to about 12 hours.

Preferred reagents for the conversion of a compound of formula (IV) into a compound of formula (V) are nitric acid, or mixtures of nitric and sulphuric acid, or potassium nitrate, or nitric acid and boron trifluoride monohydrate, or nitric acid/trifluoromethanesulfonic anhydride, at a temperature of from about -20°C to about 60°C, for a time of from a few minutes to a several hours, such as, from about 5 minutes to about 24 hours.

Preferred reducing agents for the reduction in a single step of a compound of formula (V) into the compound of formula (I) are molecular hydrogen, triethylammonium formate, formic acid, or cyclohexadiene, in the presence of suitable catalysts, such as, e.g., palladium, platinum oxide, platinum and rhodium as such or supported on carbon, CaCO₃, BaSO₄, silica or alumina,

in a suitable solvent, such as, e.g., DMF, MeOH, acetic acid, CHCl_3 , dioxane, or mixtures thereof, optionally in the presence of a suitable organic base such as, e.g., pyridine or 2,6-alkyldisubstituted pyridines such as, e.g., 2,6-lutidine etc., or inorganic base such as, e.g., sodium or calcium carbonate etc., at a temperature of from about room temperature to about 80°C , for a time of from about 1 hour to about 2 days, and at a pressure of from about 1 atm to about 50 atm, and more preferably from about 1 to about 10 atm.

When alternatively, the reduction of a compound of formula (V) is performed in two separate steps, the preferred reagents for the first step are the same as those described above for the reduction of a compound of formula (V) in a single step, for shorter times, e.g., for times of from a few minutes, such as 5 minutes to about 6 hours, if desired, isolating the intermediate derivative of formula (VI), and then performing the second reductive step of a compound of formula (VI), following the same reductive procedure as described above for the reduction of a compound of formula (V) in a single step.

Preferred reagents for the radical removal of halogens, are $n\text{-Bu}_3\text{SnH}$, in the presence of radical initiators, such as AIBN, or tris(trimethyl)silane, etc., in suitable solvents such as benzene, toluene, CHCl_3 , acetonitrile,


DMF, or mixtures thereof, at a temperature of from room temperature to solvent reflux temperature, for a time of from few minutes to several hours, such as, from 5 minutes to 24 hours.

5 The mild reaction conditions, characterizing the process of the present invention, allow the (S) configuration at C₂₀ of the compound of formula (II) to be saved in the final compound 9-amino camptothecin of formula (I).

10 The starting compound of formula (II) is a known compound and may be prepared by known methods.

The present invention includes also in its scope a process for preparing 9-amino camptothecin of formula (I) by

15 (a) nitration of camptothecin of formula (VII)



(VII)

20

to give a mixture of 9-nitro-20(S)-camptothecin and 12-nitro-20(S)-camptothecin;

(b) separation of the 9-nitro-20(S)-camptothecin from the
25 12-nitro-20(S)-camptothecin;

(c) reduction of the separated 9-nitro-20(S)-camptothecin,

to form thereby 9-amino-20(S)-camptothecin; and
(d) recycling the separated 12-nitro-20(S)-
camptothecin through the said process steps (1)
to (4) or process steps (1) to (3), (5) and (6)
5 also to form thereby 9-amino camptothecin.

The present invention according to another aspect
provides a process for the preparation of 9-amino
camptothecin of formula (I) as defined hereinbefore
comprising:

10 reducing a compound of formula (V) as defined
hereinbefore under such conditions that 9-amino
camptothecin is formed in a single step.

Preferably compound (V) is prepared by reacting a
compound of formula (IV) as defined hereinbefore with a
15 nitrating agent. The compound of formula (IV) may be
prepared by converting a compound of formula (III) as
defined hereinbefore into a compound of formula (IV). The
compound of formula (III) may be prepared by reducing a
compound of formula (II) as hereinbefore defined.

20 The present invention according to a still further
aspect provides a process for the preparation of 9-amino
camptothecin of formula (I) as defined hereinbefore
comprising reductively removing the X group from a
compound of formula (VI) as defined hereinbefore. The
25 compound of formula (VI) may be prepared by reducing a
compound of formula (V) under such conditions that the
compound of formula (VI) is obtained.

A further object of the present invention is a
process for preparing camptothecin of the above formula
30 (VII) comprising the reductive removal of the X group
from compound of the above formula (IV).

The reductive removal of X the group from a compound
of formula (IV) to obtain the camptothecin of formula
(VII) may be carried out by using suitable reducing
35 agents chosen from, e.g., molecular hydrogen or, for
instance, triethylammonium formate, formic acid,
cyclohexadiene, etc., in the presence of suitable
catalysts, such as, e.g., palladium, platinum oxide,

platinum, rhodium or ruthenium, as such or supported on a suitable medium, such as on carbon, on CaCO_3 , on BaSO_4 , on alumina, etc., in a suitable solvent such as DMF, MeOH, acetic acid, CHCl_3 , dioxane, or mixtures thereof, in the

5 presence of a suitable organic base, such as, for instance, pyridine or 2,6-alkyldisubstituted pyridines, such as, e.g., 2,6-lutidine, etc., at a temperature of from about 0°C to about 100°C , for a time of from about 1 hour to about 3 days, and at a pressure of from about 1

10 to about 100 atm.

Preferred reducing agents, when in a compound of formula (IV) X is halogen, are molecular hydrogen, triethylammonium formate, formic acid, or cyclohexadiene, in the presence of suitable catalysts, such as, e.g., palladium, platinum oxide, platinum and rhodium as such, or supported on carbon, CaCO_3 , BaSO_4 , silica or alumina, in DMF, MeOH, acetic acid, CHCl_3 , dioxane, or mixtures thereof, at a temperature of from about room temperature to about 80°C , for a time of from about 1 hour to about 24 hours, in the presence of an organic base, the preferred being pyridine, and 2,6-lutidine, and at a pressure of from 1 about atm to about 50 atm, and more preferably from about 1 to about 10 atm.

The 9-amino camptothecin of formula (I) and the camptothecin of formula (VII) are useful as inhibitors of topoisomerase I. They are useful in the treatment of cancers, in particular leukaemia, colon and rectal tumours. The compounds may therefore be used to improve the condition of a patient suffering from such a cancer. They can be also used to alleviate such a cancer.

An effective amount of the 9-amino camptothecin or the camptothecin may thus be administered to a host in need thereof, typically a human. The active compound can be administered by an appropriate route, for example orally or parenterally such as, e.g., intravenously. A dose of from 0.1 to 60 mg of active compound can be given

to a human patient per Kg body weight by these routes. A preferred dosage range is from 1 to 40 mg per Kg body weight.

The 9-amino camptothecin of formula (I) or the
5 camptothecin of formula (VII) may be formulated for administrative purposes into a pharmaceutical composition with a pharmaceutically carrier or diluent. Any suitable carrier or diluent may be employed, depending upon the route of administration. Suitable types of formulations
10 are described in US-A-5106742 and WO91/05556.

The following Examples illustrate the preparation of the intermediates and compounds of the present invention and do not limit the scope of the invention.

15 Example 1

12-amino-20(S)-camptothecin

To a stirred solution/suspension of 12-nitro-20(S)-camptothecin (20g) in conc. HCl (300 ml), anhydrous SnCl₂ (41.9 g) was added at 0-5°C, and the resulting mixture
20 was stirred continuously at room temperature overnight. The solid is filtered and washed with small amounts of conc. HCl. The yellow solid was then suspended in water, and the pH adjusted to about 2 with solid sodium bicarbonate added in portions. The solid was collected by
25 filtration, washed with water till neutral, then with ethanol and diethyl ether. After drying 10.5 g of the title compound were obtained.

19

¹NMR (DMSO-d₆), δ ppm: 0.88 (3H, t, J = 7.2 Hz); 1.83 (2H, m); 5.22 (2H, s); 5.40 (2H, s); 6.19 (2H, bs); 6.50 (1H, s) 6.9-7.4 (3H, m); 8.44 (1H, s).

5 Example 2

12-amino-20(S)-camptothecin.

A solution of 12-nitro-20(S)-camptothecin (1g) in DMF (100 ml) was hydrogenated at atmospheric pressure and room temperature in the presence of 10% Pd/C (0.25 g) until H₂ consumption ceased. The resulting suspension was diluted with an equal amount of DMF and filtered. The solution was concentrated *in vacuo* to small volume and the precipitated yellow solid was collected by filtration, washed with ethanol and ether. The title product was obtained as a yellow solid (0.8 g).

It had the same physical properties of the compound of Example 1.

Example 3

12-chloro-20(S)-camptothecin.

20 Sodium nitrite (2.4 g) in 30 ml water, was added to 12-amino camptothecin (9 g) in 18% HCl (650 ml) at 0-5°C with stirring. After 30 minutes the reaction mixture was dropped into a flask containing CuCl (12.2 g) and 18% HCl (250 ml) at a temperature of 70°C. Heating was continued for 1.5 hours. The reaction mixture was then poured into ice-water, and the aqueous mixture extracted with

methylene chloride. The solvent was removed in vacuo and the solid taken up with ether, and filtered again to yield 5.5 g of the title product.

5 ¹NMR (DMSO-d₆), δ ppm: 0.89 (3H, t, J = 7.3 Hz); 1.86 (2H, m); 5.29 (2H, s); 5.42 (2H, s); 6.57 (1H, s); 7.36 (1H, s); 7.66 (1H, t, J = 7.9 Hz) 8.0-8.1 (2H, m); 8.75 (1H, s).

Example 4

10 12-bromo-20(S)-camptothecin.

Sodium nitrite (2.4 g) in 30 ml water, was added to 12-amino-20(S)-camptothecin (9 g) in 16% HBr (650 ml) at 0-5°C with stirring. After 30 minutes the reaction mixture was dropped into a flask containing CuBr (21.3 g) and 16%
15 HBr (250 ml) at a temperature of 70°C. Heating was continued for 1.5 hours. The reaction mixture was poured in ice-water, and the aqueous mixture extracted with ethyl acetate. After evaporation of the solvent, the pure product was isolated by precipitation with ether. The
20 title product was obtained as a yellow solid (6.1 g).

¹NMR (DMSO-d₆), δ ppm: 0.88 (3H, t, J = 7.3 Hz); 1.86 (2H, m); 5.31 (2H, s); 5.43 (2H, s); 6.58 (1H, s); 7.37 (1H, s); 7.60 (1H, t, J = 7.9 Hz); 8.1-8.2 (2H, m); 8.74 (1H, s).
25

Example 59-nitro-12-Chloro-20(S)-camptothecin.

12-chloro-20(S)-camptothecin (5 g) was dissolved/suspended in conc. H_2SO_4 (70 ml) and cooled to 0-5°C with mechanical stirring. 70% HNO_3 (2.7 ml) was dropped into the reaction mixture over 20 minutes, and the reaction flask was then left to warm to room temperature. The stirring was continued overnight at room temperature. The reaction mixture was poured into ice-water, and the yellow solid was collected by filtration, washed with water, ethanol and ether. After drying there were obtained 4g of the title product.

1H NMR ($DMSO-d_6$), δ ppm: 0.89 (3H, t, $J = 7.2$ Hz); 1.86 (2H, m); 5.34 (2H, s); 5.44 (2H, s); 6.61 (1H, s); 7.39 (1H, s); 8.24 (1H, d, $J = 8.3$ Hz); 8.48 (1H, d, $J = 8.3$ Hz); 9.22 (1H, s).

Example 69-nitro-12-bromo-20(S)-camptothecin.

12-bromo-20(S)-camptothecin (5.5 g) was dissolved/suspended in conc. H_2SO_4 (80 ml) and cooled to 0-5°C with mechanical stirring. 70% HNO_3 (3.1 ml) was dropped into the reaction mixture over 20 minutes, and the reaction flask was then left to warm to room temperature. The stirring was continued overnight at room

temperature. The reaction mixture was poured into ice-water, and the yellow solid was collected by filtration, washed with water, ethanol and ether. After drying there were obtained 4.2 g of the title product.

- 5 ¹NMR (DMSO-d₆), δ ppm: 0.88 (3H, t, J = 7.3 Hz); 1.87 (2H, m); 5.35 (2H, s); 5.44 (2H, s); 6.61 (1H, s); 7.40 (1H, s); 8.39 (1H, d, J = 8.4 Hz); 8.45 (1H, d, J = 8.4 Hz); 9.20 (1H, s).
- 10

Example 7

9-amino-12-chloro-20(S)-camptothecin.

- A solution of 9-nitro-12-chloro-20(S)-camptothecin (3 g) in DMF (50 ml) was hydrogenated at atmospheric pressure and temperature in presence of 10% Pd/C (0.1 g) for 2 hours. The reaction mixture was filtered, and the solution was concentrated in vacuo. The residue was chromatographed on a silica gel column to yield the title compound (2.5 g).
- 15

- 20 ¹NMR (DMSO-d₆), δ ppm: 0.87 (3H, t, J = 7.2 Hz); 1.85 (2H, m); 5.28 (2H, s); 5.42 (2H, s); 6.30 (2H, bs); 6.56 (1H, s); 6.75 (1H, d, J = 8.4 Hz); 7.31 (1H, s); 7.66 (1H, d, J = 8.4 Hz); 8.89 (1H, s).
- 25

Example 89-amino-20(S)-camptothecin.

A solution of 9-nitro-12-chloro-20(S)-camptothecin (3 g) in DMF (50 ml) was hydrogenated at atmospheric pressure and temperature in presence of 10% Pd/C (0.1 g) for 48 hours. The reaction mixture was filtered, and the solution was concentrated *in vacuo*. The residue was chromatographed on a silica gel column to yield the title compound (1.5 g).

10 ¹NMR (DMSO-*d*₆), δ ppm: 0.87 (3H, t, J = 7.3 Hz); 1.85 (2H, m); 5.26 (2H, s); 5.41 (2H, s); 6.11 (2H, s); 6.50 (1H, s); 6.79 (1H, m); 7.28 (1H, s); 7.3-7.5 (2H, m); 8.83 (1H, s).

15 Example 99-amino-20(S)-camptothecin.

A solution of 9-nitro-12-bromo-20(S)-camptothecin (3 g) in DMF (50 ml) was hydrogenated at atmospheric pressure and temperature in presence of 10% Pd/C (0.1 g) for 6 hours. The reaction mixture was filtered, and the solution was concentrated *in vacuo*. The residue was chromatographed on a silica gel column to yield the title compound (2.0 g). This compound had identical characteristic as the compound obtained in Example 8.

Example 10

9-amino-20(S)-camptothecin from 9-amino-12-chloro-20(S)-camptothecin.

5 The reaction was performed as in Example 8 to yield the title product as a yellow solid, which was identical to the authentic product.

Example 11

20(S)-camptothecin from 12-chloro-20(S)-camptothecin.

10 The reaction was performed as in Example 8, except that the reaction was performed in the presence of pyridine, and the reaction mixture was hydrogenated for 12 hours. The title product was isolated by column chromatography. It was identical to a sample of the authentic product.


Example 12

15 20(S)-camptothecin from 12-bromo-20(S)-camptothecin.

The reaction was performed as in Example 11, except that the reaction was carried out for 6 hours, to yield the title product, which was identical to a sample of the authentic material.

CLAIMS


1. A process for preparing the 9-amino camptothecin of formula (I)



(I)


said process comprising:

- (1) reducing the compound of formula (II)



(II)

so obtaining the compound of formula (III)




(III)

- (2) converting the compound of formula (III) into a

26

compound of formula (IV)




(IV)

wherein

X is a group which can be reductively removed;

- 10 (3) reacting a compound of formula (IV) with a
nitrating agent, so obtaining a compound of
formula (V)




(V)

wherein X is as defined above;

and

- 20 (4) reducing in a single step a compound of formula
(V), so obtaining the 9-amino camptothecin of
formula (I) or, alternatively,
(5) reducing a compound of formula (V), so
25 obtaining a compound of formula (VI)

27



(VI)

wherein X is as defined above, and

(6) reductively removing the X group from a compound of formula (VI), so obtaining the 9-amino camptothecin of formula (I).

10

2. A process according to claim 1, wherein X is halogen.

15

3. A process according to claim 1 or 2, wherein step (1) is effected by using SnCl_2 , Zn or Fe as a reducing agent or by catalytic hydrogenation employing palladium, platinum oxide, platinum, rhodium or ruthenium.

20

4. A process according to any one of the preceding claims, wherein step (2) is effected by diazotisation of the compound of formula (III) and reaction of the diazotisation product with CuCl or CuBr.

25

5. A process according to any one of the preceding claims, wherein the nitrating agent in step (3) is selected from nitric acid; a mixture of nitric and sulphuric acids; potassium nitrate; nitric acid and

boron trifluoride; and nitric acid and trifluoromethansulfonic anhydride.


6. A process according to any one of the preceding
5 claims, wherein the reducing agent used in step (4) or the reducing agent(s) used in steps (5) and (6) are selected from molecular hydrogen, triethylammonium formate, formic acid, tributyltin hydride and cyclohexadiene.

10

7. A process according to any one of the preceding claims, said process comprising:

(a) nitration of camptothecin of formula (VII)

15



(VII)

20

to give a mixture of 9-nitro-20(S)-camptothecin and 12-nitro-20(S)-camptothecin;

25

- (b) separation of the 9-nitro-20(S)-camptothecin from the 12-nitro-20(S)-camptothecin;
- (c) reduction of the separated 9-nitro-20(S)-camptothecin, to form thereby 9-amino-20(S)-camptothecin; and
- (d) recycling the separated 12-nitro-20(S)-camptothecin through the said process steps (1)

to (4) or the said process steps (1) to (3), (5) and (6) also to form thereby 9-amino-20(S) camptothecin.

5 8. A process for the preparation of the 9-amino camptothecin of formula (I) as defined in claim 1, which process comprises

10 (i) reducing a compound of formula (V) as defined in claim 1 under such conditions that 9-amino camptothecin is formed in a single step; or

(ii) reductively removing the X group from a compound of formula (VI) as defined in claim 1.

15 9. A process according to claim 8, wherein the compound of formula (VI) is prepared by reducing a compound of formula (V) under such conditions that the compound of formula (VI) is obtained.

20 10. A process according to claim 8 or claim 9, wherein the compound of formula (V) is prepared by reacting a compound of formula (IV) as defined in claim 1 with a nitrating agent.

25 11. A process according to claim 10, wherein the compound of formula (IV) is prepared by converting a compound of formula (III) as defined in claim 1 into the compound of formula (IV).

30 12. A process according to claim 11, wherein the compound of formula (III) is prepared by reducing a compound of formula (II) as defined in claim 1.

13. A compound of formula (V) or (VI) as defined in claim 1.

14. A process for the preparation of a compound of formula (V) as defined in claim 1, which process comprises reacting a compound of formula (IV) as defined in claim 1, with a nitrating agent.

5 15. A process for the preparation of a compound of formula (VI) as defined in claim 1, which process comprises reducing a compound of formula (V) under such conditions that the compound of formula (VI) is obtained.

10 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, the 9-amino camptothecin of formula (I) as defined in claim 1 which has been prepared by a process as claimed in any one of claims 1 to 12.

15 17. A process for the preparation of 9-amino camptothecin according to any one of claim 1 to 12 substantially as hereinbefore described with references to the Examples.

20 18. A compound according to claim 13 substantially as hereinbefore described with reference to any one of Examples 5 to 7.

25 19. A process according to claim 14 substantially as hereinbefore described with reference to Example 5 or Example 6.

20. A process according to claim 15 substantially as hereinbefore described with reference to Example 7.

Dated this 19th day of February 1997

30

PHARMACIA & UPJOHN S.p.A.

By their Patent Attorneys

GRIFFITH HACK

INTERNATIONAL SEARCH REPORT

Inter national Application No
PCT/EP 94/02370

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D491/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 894 456 (M.E. WALL ET AL.) 16 January 1990 cited in the application see column 9, line 40 - line 50 ---	14
X	JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol.18, no.3, 1981 pages 319 - 330 P.E. RONMAN ET AL. 'The Preparation of Tritium and Deuterium-Labelled Camptothecin' see page 327, line 3 - line 22 --- -/--	13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *I* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

14 September 1994

Date of mailing of the international search report

27. 09. 94

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, fax 31 651 epo nl,
fax (+ 31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/EP 94/02370

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL AND PHARMACEUTICAL BULLETIN, vol.39, no.12, December 1991, TOKYO JP pages 3183 - 3188 S SAWADA ET AL. 'Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7,10-Disubstituted Camptothecins' cited in the application see page 3186, column 1, paragraph 7 -paragraph 8	8
A	see the whole document	1-6, 10-12
Y	EP,A,0 538 534 (RESEARCH TRIANGLE INSTITUTE) 28 April 1993 see page 3, line 19 - line 28 see page 5, line 3 - line 5	8
A	DE,A,21 50 234 (BADISCHE ANILIN- & SODA FABRIK AG) 12 April 1973 see page 4, paragraph 2	13

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 94/02370

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4894456	16-01-90	US-A- 4981968	01-01-91
		US-A- 5106742	21-04-92
		US-A- 5244903	14-09-93
		US-A- 5227380	13-07-93
		US-A- 5122526	16-06-92

EP-A-0538534	28-04-93	WO-A- 9308189	29-04-93

DE-A-2150234	12-04-73	CH-A- 570406	15-12-75
		US-A- 3894029	08-07-75
